OncoOne has developed multiple, novel oxMIF-specific antibodies advancing toward the clinic:
• Clinical candidate ON203 is a second generation, bioengineered anti-oxMIF antibody designed for optimal tumor penetration & tumor retention. ON203 inhibits MIF-mediated pro-tumorigenic signaling and exerts cytotoxic functions by inducing antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) for high therapeutic potential in solid tumors.
• Research program ON-05 comprises an anti-oxMIF radiotherapy utilizing OncoOne’s proprietary PreTarg-it® platform.
• ON102 is a radioimmunoconjugate designed to provide a non-invasive approach for diagnostic applications (pan-cancer diagnostic).
Based on these different mechanisms, our drug candidates will enable both monotherapies and innovative combination treatment approaches for patients suffering from solid tumors of the colon, ovary, pancreas, and lung. Compared to the published first generation oxMIF antibodies, all OncoOne antibody-based modalities have been significantly optimized in terms of pharmacokinetics, pharmacodynamics and bioavailability.